Technology Bundle ID
TAB-3678

Imaging Inflammation using PET Radioligands that Target Translocator Protein 18 kDa with High Affinity Regardless of Genotype

Applications
Diagnostics
Linked ID
E-072-2013-0
Lead Inventors
Victor Pike (NIMH)
Co-Inventors
Chad Brouwer (NIMH)
ICs
NIMH
This technology includes a group of radioligands that label inflammatory cells specifically, accurately, and across different genotypes and can be detected using Positron Emission Tomography (PET). The radioligands target the Translocator protein 18 kDa (TSPO) receptor which is present on the outer mitochondrial membrane and is involved in the production of steroids. Current TSPO radioligands either lack specificity or have highly variable inter-subject sensitivities due to TSPO genotypic differences. These new ligands permit a simplified interpretation and quantification of the binding signal.

During inflammation of the central nervous system, TSPO levels are increased. Neuroinflammation is symptomatic of many neuropsychiatric and neurodegenerative disorders, such as multiple sclerosis, stroke, epilepsy, dementia, and traumatic brain injuries. Thus, monitoring and quantifying TSPO with radioligands using PET may have clinical application in understanding, diagnosing, and treating many neuropsychiatric disorders.
Commercial Applications
Biomarker or diagnostic for neuroinflammation
Competitive Advantages
Radioligands are specific and accurate, regardless of genotype

Request More Info

Licensing Contact: